Skip to content

Title 42 — The Public Health and Welfare

Part B · Chapter 6A — Public Health Service

§ 284q. Pain research

Statutory text

(a)

Research initiatives

(1)

In general

The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain.

(2)

Annual recommendations

Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 282a(c)(1) of this title for the Common Fund or otherwise available for such initiatives.

(3)

Definition

In this subsection, the term “Pain Consortium” means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection.

(b)

Interagency Pain Research Coordinating Committee

(1)

Establishment

The Secretary shall establish not later than 1 year after , and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the “Committee”), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research.

(2)

Membership

(A)

In general

The Committee shall be composed of the following voting members:

(i)

Not more than 7 voting Federal representatives appoint 1 by the Secretary from agencies that conduct pain care research and treatment.

(ii)

12 additional voting members appointed under subparagraph (B).

(B)

Additional members

The Committee shall include additional voting members appointed by the Secretary as follows:

(i)

6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.

(ii)

6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.

(C)

Nonvoting members

The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

(3)

Chairperson

The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.

(4)

Meetings

The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.

(5)

Duties

The Committee shall—

(A)

develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;

(B)

identify critical gaps in basic and clinical research on—

(i)

the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;

(ii)

the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and

(iii)

risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and

(C)

make recommendations to the Director of NIH—

(i)

to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;

(ii)

on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and

(iii)

on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

(6)

Report

The Secretary shall ensure that recommendations and actions taken by the Director with respect to the topics discussed at the meetings described in paragraph (4) are included in appropriate reports to Congress.

(7)

Review

The Secretary shall review the necessity of the Committee at least once every 2 years.

Footnotes

  1. 1 So in original. Probably should be “appointed”.

Legislative history

Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.

  1. Patient Protection and Affordable Care Act

    Pub. L. 111–148 title IV § 4305(b) · 124 Stat. 119

    Enacted · 42 U.S.C. § 284q

    July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585

    Source evidence

    Code source credit
    July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585

    Enacted provision · exact public law section
    (b) Pain Research at National Institutes of Health.— Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding at the end the following: “SEC. 409J. PAIN RESEARCH. “(a) Research Initiatives.— “(1) In general.— The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain. “(2) Annual recommendations.— Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 402A(c)(1) for the Common Fund or otherwise available for such initiatives. “(3) Definition.— In this subsection, the term ‘Pain Consortium’ means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection. “(b) Interagency Pain Research Coordinating Committee.— “(1) Establishment.— The Deadline. Secretary shall establish not later than 1 year after the date of the enactment of this section and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the ‘Committee’), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research. “(2) Membership.— “(A) In general.— The Committee shall be composed of the following voting members: “(i) Not more than 7 voting Federal representatives appoint by the Secretary from agencies that conduct pain care research and treatment. “(ii) 12 additional voting members appointed under subparagraph (B). “(B) Additional members.— The Committee shall include additional voting members appointed by the Secretary as follows: “(i) 6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals. “(ii) 6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions. “(C) Nonvoting members.— The Committee shall include such nonvoting members as the Secretary determines to be appropriate. “(3) Chairperson.— The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH. “(4) Meetings.— The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year. “(5) Duties.— The Committee shall— “(A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, and treatment of pain and diseases and disorders associated with pain; “(B) identify critical gaps in basic and clinical research on the symptoms and causes of pain; “(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(D) make recommendations on how best to disseminate information on pain care; and “(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research. “(6) Review.— The Secretary shall review the necessity of the Committee at least once every 2 years.” .

  2. Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act

    Pub. L. 115–271 § 7042(1)(A) · 132 Stat. 3894

    Substituted · 42 U.S.C. § 284q(b)(5)(A)

    Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”

    Source evidence

    Code amendment note
    Subsec. (b)(5)(A). Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”.

    Enacted provision · exact public law section
    (A) in subparagraph (A), by striking “and treatment of pain and diseases and disorders associated with pain” and inserting “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration”;

  3. Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act

    Pub. L. 115–271 § 7042(1)(B) · 132 Stat. 3894

    Substituted · 42 U.S.C. § 284q(b)(5)(B)

    Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”

    Source evidence

    Code amendment note
    Subsec. (b)(5)(B). Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”.

    Enacted provision · exact public law section
    (B) in subparagraph (B), by striking “on the symptoms and causes of pain;” and inserting the following: “on— “(i) the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain; “(ii) the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and “(iii) risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and” ; and

  4. Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act

    Pub. L. 115–271 § 7042(1)(C) · 132 Stat. 3894

    1. Added · 42 U.S.C. § 284q(b)(5)(C)(E)

      Pub. L. 115–271, § 7042(1)(C), added subpar. (C)

    2. Struck · 42 U.S.C. § 284q(b)(5)(C)(E)

      Pub. L. 115–271, § 7042(1)(C), struck out former subpars. (C) to (E) which read as follows:

    Source evidence

    Code amendment note
    Subsec. (b)(5)(C) to (E). Pub. L. 115–271, § 7042(1)(C), added subpar. (C) and struck out former subpars. (C) to (E) which read as follows:

    “(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(D) make recommendations on how best to disseminate information on pain care; and “(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.”

    Enacted provision · exact public law section
    (C) by striking subparagraphs (C) through (E) and inserting the following: “(C) make recommendations to the Director of NIH— “(i) to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(ii) on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and “(iii) on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.” ;

  5. Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act

    Pub. L. 115–271 § 7042(2) · 132 Stat. 3894

    1. Added · 42 U.S.C. § 284q(b)(6); 42 U.S.C. § 284q(b)(7)

      Pub. L. 115–271, § 7042(2), (3), added par. (6)

    2. Redesignated · 42 U.S.C. § 284q(b)(6); 42 U.S.C. § 284q(b)(7)

      Pub. L. 115–271, § 7042(2), (3), redesignated former par. (6) as (7)

    Source evidence

    Code amendment note
    Subsec. (b)(6), (7). Pub. L. 115–271, § 7042(2), (3), added par. (6) and redesignated former par. (6) as (7).

    Enacted provision · exact public law section
    (2) by redesignating paragraph (6) as paragraph (7); and

7 of 7 references resolved to an enrolled provision

Editorial Notes

Amendments

2018—Subsec. (b)(5)(A). Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”.

Subsec. (b)(5)(B). Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”.

Subsec. (b)(5)(C) to (E). Pub. L. 115–271, § 7042(1)(C), added subpar. (C) and struck out former subpars. (C) to (E) which read as follows:

“(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;

“(D) make recommendations on how best to disseminate information on pain care; and

“(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.”

Subsec. (b)(6), (7). Pub. L. 115–271, § 7042(2), (3), added par. (6) and redesignated former par. (6) as (7).

Credits

1944–2018 · 2 acts
  1. 1944July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), , 124 Stat. 585
  2. 2018amended Pub. L. 115–271, title VII, § 7042, , 132 Stat. 4016.
Show as published

(July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), , 124 Stat. 585; amended Pub. L. 115–271, title VII, § 7042, , 132 Stat. 4016.)

Parsed from the official OLRC USLM XML in data/usc_all/usc42.xml · release point 119-108 · OLRC build 2026-09-09

USLM identifier /us/usc/t42/s284q